Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neurotech International ( (AU:NTI) ) has provided an update.
Neurotech International has disclosed a change in director Gerald Quigley’s interests, confirming the lapse of 5,000,000 unlisted options (NTIOPT20, exercisable at $0.10 and expiring 23 December 2025), which were held directly. Following this lapse, Quigley’s remaining interest is an indirect holding of 277,777 fully paid ordinary shares via a nominee and custodial structure, with no cash consideration involved and no trades occurring during a closed period, indicating a reduction in his potential equity exposure while leaving his existing shareholding intact.
More about Neurotech International
Neurotech International Limited is an ASX-listed company, operating in the broader biotechnology and medical technology sector. It focuses on developing and commercialising neurotechnology-related products and services, targeting applications in neurological health and related therapeutic or monitoring markets.
Average Trading Volume: 1,220,445
Technical Sentiment Signal: Sell
Current Market Cap: A$17.84M
Find detailed analytics on NTI stock on TipRanks’ Stock Analysis page.